- Home
- PHAT vs ACP Comparison
PHAT vs ACP Comparison
Compare PHAT & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ACP
- Stock Information
- Founded
- PHAT 2018
- ACP 2010
- Country
- PHAT United States
- ACP United States
- Employees
- PHAT N/A
- ACP N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- PHAT Health Care
- ACP Finance
- Exchange
- PHAT Nasdaq
- ACP Nasdaq
- Market Cap
- PHAT 727.5M
- ACP 737.8M
- IPO Year
- PHAT 2019
- ACP N/A
- Fundamental
- Price
- PHAT $9.80
- ACP $5.88
- Analyst Decision
- PHAT Strong Buy
- ACP
- Analyst Count
- PHAT 5
- ACP 0
- Target Price
- PHAT $16.40
- ACP N/A
- AVG Volume (30 Days)
- PHAT 4.9M
- ACP 337.9K
- Earning Date
- PHAT 08-07-2025
- ACP 01-01-0001
- Dividend Yield
- PHAT N/A
- ACP 17.79%
- EPS Growth
- PHAT N/A
- ACP N/A
- EPS
- PHAT N/A
- ACP N/A
- Revenue
- PHAT $81,859,000.00
- ACP N/A
- Revenue This Year
- PHAT $195.45
- ACP N/A
- Revenue Next Year
- PHAT $106.76
- ACP N/A
- P/E Ratio
- PHAT N/A
- ACP N/A
- Revenue Growth
- PHAT 3055.70
- ACP N/A
- 52 Week Low
- PHAT $2.21
- ACP $5.55
- 52 Week High
- PHAT $19.71
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- PHAT 66.25
- ACP 54.62
- Support Level
- PHAT $8.86
- ACP $5.73
- Resistance Level
- PHAT $11.21
- ACP $5.93
- Average True Range (ATR)
- PHAT 1.59
- ACP 0.04
- MACD
- PHAT -0.06
- ACP -0.01
- Stochastic Oscillator
- PHAT 63.60
- ACP 70.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.